EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER

Cristiane Bergerot iD, Shengsheng Yu iD, Min Yang iD, Bruno Martins iD, Mengtian Du, Jose Perez Torrealba, Tasha Hall iD, Navendu Samant, Robert J Motzer iD, David Cella iD

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag329 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Oncologist, 2026. Verfasst von Cristiane Bergerot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Oncoclínicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo 01309-001, Brazil. Hauptthemen laut MEDLINE: Anilides, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Bristol Myers Squibb in collaboration with Exelixis, Ipsen Pharma, and Takeda Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivolumab plus cabozantinib demonstrated significantly better clinical and patient-reported outcomes (PROs) compared with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) in CheckMate 9ER. This post-hoc analysis identified key factors contributing to improvements in health-related quality of life (HRQOL) in these patients. Materials and Methods Mediation analyses were conducted using first-year CheckMate 9ER data to delineate treatment effects as reflected by HRQOL improvements measured with the EuroQoL 5-Dimension 3-Level questionnaire (EQ-5D-3L) and 19-item Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19) Functional Well-Being Subscale (FKSI-FWB). The incremental benefits of nivolumab plus cabozantinib over sunitinib were partitioned into mediated effects through symptom and emotional well-being improvements (FKSI-19 scales).

Results

Nivolumab plus cabozantinib (n = 323) resulted in significantly greater improvement in EQ-5D utility versus sunitinib (n = 328; difference = 0.08 [95% confidence interval [CI], 0.05-0.12]) and numerically greater FKSI-FWB improvement (difference = 0.22 [95% CI, –0.19 to 0.63]), both primarily driven by greater reductions in fatigue, pain, shortness of breath, and cough, and improvements in emotional well-being (all P < 0.05). Reduced fatigue was the largest contributor to gains in both scales (24.0% and 21.1% of total mediated effect, respectively); improvement in emotional well-being accounted for 5.0% and 17.2% of the total mediated effect.

Conclusion

These findings highlight underlying pathways contributing to HRQOL improvement in patients with aRCC receiving nivolumab plus cabozantinib. These data suggest that treatment with nivolumab plus cabozantinib is associated with an improvement in symptoms that can be quantified using PRO measures, supporting the utility of incorporating patient-centric outcomes into treatment decision making. ClinicalTrials.gov NCT03141177

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellKidney NeoplasmsNivolumabPyridinesQuality of LifeSunitinibAgedFemaleHumansMaleMiddle AgedPatient Reported Outcome Measures

Stichwörter der Autor:innen

advanced renal cell carcinomacabozantinibhealth-related quality of lifenivolumabpatient-reported outcomes

Substanzen

AnilidescabozantinibNivolumabPyridinesSunitinib

Autor:innen und Institutionen

  • Oncoclínicas&Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo 01309-001, Brazil.
  • Exelixis, Inc., Alameda, CA 94502, United States.
  • Analysis Group, Inc., Boston, MA 02199, United States.
  • Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
  • Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States.

ORCID-Profile: Cristiane Bergerot, Shengsheng Yu, Min Yang, Bruno Martins, Tasha Hall, Robert J Motzer, David Cella

Förderung

  • NCI NIH HHS
  • Bristol Myers Squibb in collaboration with Exelixis, Ipsen Pharma, and Takeda Pharmaceuticals

Zitieren

APA

Bergerot, C., Yu, S., Yang, M., Martins, B., Du, M., Perez Torrealba, J., Hall, T., Samant, N., Motzer, R. J., & Cella, D. (2026). Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER. The Oncologist. https://doi.org/10.1093/oncolo/oyag329

Vancouver

Bergerot C, Yu S, Yang M, Martins B, Du M, Perez Torrealba J, et al. Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER. The Oncologist. 2026. doi:10.1093/oncolo/oyag329

BibTeX
@article{Bergerot2026,
  author = {Bergerot, Cristiane and Yu, Shengsheng and Yang, Min and Martins, Bruno and Du, Mengtian and Perez Torrealba, Jose and Hall, Tasha and Samant, Navendu and Motzer, Robert J and Cella, David},
  title = {Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag329}
}
Kostenlos starten →